Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
Kiyoaki UryuYoshinori ImamuraRai ShimoyamaTakahiro MaseYoshiaki FujimuraMaki HayashiMegu OhtakiKeiko OtaniMakoto HibinoShigeto HoriuchiTomoya FukuiRyuta FukaiYusuke ChiharaAkihiko IwaseNoriko YamadaYukihiro TamuraHiromasa HaradaNobuaki ShinozakiAsuka TsuyaMasahiro FukuokaHironobu MinamiPublished in: Japanese journal of clinical oncology (2023)
Our real-world data revealed that the swift and widespread utilization of newer-generation EGFR-TKIs in patients with EGFR mutation-positive non-small-cell lung cancer, and that these newer-generation EGFR-TKIs can prolong overall survival regardless of hospital volume or type. Therefore, osimertinib could be a reasonable first choice treatment for these patients across various clinical practice settings.
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- end stage renal disease
- clinical practice
- chronic kidney disease
- ejection fraction
- electronic health record
- newly diagnosed
- big data
- prognostic factors
- emergency department
- machine learning
- single cell
- deep learning
- artificial intelligence
- drug induced